X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Lupin Ltd with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs TEVA PHARMA (Israel) - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 LUPIN LTD   TEVA PHARMA
EQUITY SHARE DATA
    LUPIN LTD
Mar-18
TEVA PHARMA
Dec-13
LUPIN LTD/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,4653,083-   
Low Rs7272,679-   
Sales per share (Unadj.) Rs349.61,769.6-  
Earnings per share (Unadj.) Rs5.6110.5-  
Cash flow per share (Unadj.) Rs29.6253.6-  
Dividends per share (Unadj.) Rs5.0096.77-  
Dividend yield (eoy) %0.53.4 13.6%  
Book value per share (Unadj.) Rs300.31,965.7-  
Shares outstanding (eoy) m452.08848.00-   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x3.11.6 192.6%   
Avg P/E ratio x197.226.1 756.7%  
P/CF ratio (eoy) x37.111.4 326.2%  
Price / Book Value ratio x3.61.5 249.0%  
Dividend payout %90.087.5 102.8%   
Avg Mkt Cap Rs m495,5022,443,029 20.3%   
No. of employees `00017.044.9 37.9%   
Total wages/salary Rs m28,6470-   
Avg. sales/employee Rs Th9,273.633,387.4 27.8%   
Avg. wages/employee Rs Th1,681.00-   
Avg. net profit/employee Rs Th147.42,085.7 7.1%   
INCOME DATA
Net Sales Rs m158,0421,500,595 10.5%  
Other income Rs m1,5040-   
Total revenues Rs m159,5451,500,595 10.6%   
Gross profit Rs m31,475410,939 7.7%  
Depreciation Rs m10,859121,295 9.0%   
Interest Rs m2,04429,474 6.9%   
Profit before tax Rs m20,076260,170 7.7%   
Minority Interest Rs m-711,182 -6.0%   
Prior Period Items Rs m350-   
Extraordinary Inc (Exp) Rs m-14,644-170,787 8.6%   
Tax Rs m2,885-3,176 -90.8%   
Profit after tax Rs m2,51393,741 2.7%  
Gross profit margin %19.927.4 72.7%  
Effective tax rate %14.4-1.2 -1,176.8%   
Net profit margin %1.66.2 25.4%  
BALANCE SHEET DATA
Current assets Rs m122,0951,013,496 12.0%   
Current liabilities Rs m50,956883,855 5.8%   
Net working cap to sales %45.08.6 521.0%  
Current ratio x2.41.1 209.0%  
Inventory Days Days8591 93.2%  
Debtors Days Days12096 125.0%  
Net fixed assets Rs m129,876490,127 26.5%   
Share capital Rs m9043,694 24.5%   
"Free" reserves Rs m134,8660-   
Net worth Rs m135,7711,666,877 8.1%   
Long term debt Rs m64,245767,288 8.4%   
Total assets Rs m263,0543,429,341 7.7%  
Interest coverage x10.89.8 110.2%   
Debt to equity ratio x0.50.5 102.8%  
Sales to assets ratio x0.60.4 137.3%   
Return on assets %1.73.6 48.2%  
Return on equity %1.95.6 32.9%  
Return on capital %3.74.9 75.4%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m33,8070-   
CASH FLOW
From Operations Rs m17,512239,117 7.3%  
From Investments Rs m-14,073-84,729 16.6%  
From Financial Activity Rs m-14,921-286,837 5.2%  
Net Cashflow Rs m-11,482-132,449 8.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 73.87 Rs / USD

Compare LUPIN LTD With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare LUPIN LTD With: DISHMAN PHARMA  ALKEM LABORATORIES  TTK HEALTHCARE  BIOCON LTD  GLENMARK PHARMA  



Today's Market

Indian Indices Trade Strong; Capital Goods Stocks Lead Gains(12:30 pm)

After opening the day in green, share markets in India have continued the momentum and are presently trading above the dotted line.

Related Views On News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

LUPIN LTD Announces Quarterly Results (1QFY19); Net Profit Up 21.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, LUPIN LTD has posted a net profit of Rs 4 bn (up 21.3% YoY). Sales on the other hand came in at Rs 26 bn (up 3.2% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

LUPIN LTD Announces Quarterly Results (4QFY18); Net Profit Down 305.5% (Quarterly Result Update)

Jul 19, 2018 | Updated on Jul 19, 2018

For the quarter ended March 2018, LUPIN LTD has posted a net profit of Rs 8 bn (down 305.5% YoY). Sales on the other hand came in at Rs 40 bn (down 5.2% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Why You Should Be Excited, Not Sad, About the 30% Small Cap Crash(Profit Hunter)

Oct 4, 2018

Smallcaps have corrected over 30% since the beginning of the year. Find out why Richa Agarwal views this as an opportunity rather than a threat.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

Why Are Investors In Sundaram Small Cap Fund Anxious(Outside View)

Oct 3, 2018

A small cap fund that aims to capitalise on emerging businesses and catch them young. However, its failure in keeping volatility under check is making its investors anxious.

Biggest Corrections in the Stock of Infibeam Avenues(Chart Of The Day)

Oct 3, 2018

Infibeam plunged over 70% last week. This was the second biggest single-day fall. But Infibeam witnessed such sharp falls earlier.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Oct 16, 2018 01:39 PM

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD - WYETH LTD COMPARISON

COMPARE LUPIN LTD WITH

MARKET STATS